ea0070oc7.5 | Endocrine-related Cancer | ECE2020
Weigand Isabel
, Sbiera Silviu
, Kendl Sabine
, Hanna Urlaub
, Constanze Hantel
, Katja Kiseljak-Vassiliades
, Margaret E Wierman
, Fassnacht Martin
, Kroiss Matthias
Background: Mitotane is the only approved treatment for advanced adrenocortical carcinoma and was shown to inhibit Sterol-O-Acyl transferase 1 (SOAT1) which leads to the depletion of cholesterol esters and increase of free cholesterol in the ACC cell line H295R. Downstream activation of the endoplasmic reticulum stress (ER-stress) pathway results in decreased adrenocortical cell viability.Aim: To better characterize the effects of SOAT1 inhibition in ACC...